Overview

A Study of LY2624803 in Participants With Transient Insomnia

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy people. The study has four treatment periods. Participants will receive a single dose of LY2624803, another sleeping pill, or placebo in each treatment period. The study will last approximately 1 month for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Zolpidem